CR20180111A - Agentes antibacteriales que comprenden una pirazino[2,3-b] [1,4] oxazin-3-ona o un sistema de anillos relacionado - Google Patents

Agentes antibacteriales que comprenden una pirazino[2,3-b] [1,4] oxazin-3-ona o un sistema de anillos relacionado

Info

Publication number
CR20180111A
CR20180111A CR20180111A CR20180111A CR20180111A CR 20180111 A CR20180111 A CR 20180111A CR 20180111 A CR20180111 A CR 20180111A CR 20180111 A CR20180111 A CR 20180111A CR 20180111 A CR20180111 A CR 20180111A
Authority
CR
Costa Rica
Prior art keywords
pirazino
oxazin
ona
understanding
ring system
Prior art date
Application number
CR20180111A
Other languages
English (en)
Inventor
Alan; Hennessy
Neil David; Pearson
Haifeng; Cui
Qi Jin
Timothy James; Miles
Stephen Frederick; Moss
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of CR20180111A publication Critical patent/CR20180111A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a nuevos compuestos o sales farmacéuticamente aceptables de los mismos, que corresponden a composiciones farmacéuticas y procedimientos de tratamiento o usos como antibacterianos para infecciones bacterianas.
CR20180111A 2015-08-16 2016-08-15 Agentes antibacteriales que comprenden una pirazino[2,3-b] [1,4] oxazin-3-ona o un sistema de anillos relacionado CR20180111A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562205732P 2015-08-16 2015-08-16
US201662308928P 2016-03-16 2016-03-16
PCT/IB2016/054890 WO2017029602A2 (en) 2015-08-16 2016-08-15 Compounds for use in antibacterial applications

Publications (1)

Publication Number Publication Date
CR20180111A true CR20180111A (es) 2018-04-12

Family

ID=57218948

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20180111A CR20180111A (es) 2015-08-16 2016-08-15 Agentes antibacteriales que comprenden una pirazino[2,3-b] [1,4] oxazin-3-ona o un sistema de anillos relacionado

Country Status (22)

Country Link
US (2) US10364254B2 (es)
EP (1) EP3334739A2 (es)
JP (1) JP6757402B2 (es)
KR (1) KR20180038046A (es)
CN (1) CN108137616B (es)
AU (2) AU2016307969C1 (es)
CA (1) CA2995715A1 (es)
CL (1) CL2018000403A1 (es)
CO (1) CO2018002204A2 (es)
CR (1) CR20180111A (es)
DO (1) DOP2018000049A (es)
EA (1) EA033314B1 (es)
HK (1) HK1248680A1 (es)
IL (1) IL257265B (es)
MA (1) MA42621A (es)
MX (1) MX2018002033A (es)
PE (1) PE20181143A1 (es)
PH (1) PH12018500358A1 (es)
TW (1) TW201722965A (es)
UY (1) UY36851A (es)
WO (1) WO2017029602A2 (es)
ZA (1) ZA201800722B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201722965A (zh) * 2015-08-16 2017-07-01 葛蘭素史密斯克藍智慧財產發展有限公司 用於抗菌應用之化合物
WO2019180634A1 (en) 2018-03-23 2019-09-26 Glaxosmithkline Intellectual Property Development Limited Synthesis of oxazinone-containing bicyclic aromatic and heteroaromatic aldehydes
TW202116782A (zh) 2019-07-16 2021-05-01 瑞士商愛杜西亞製藥有限公司 喹啉酮衍生物
CN111269247B (zh) * 2020-03-04 2020-11-24 河南科技大学第一附属医院 具有抑制大肠杆菌作用的噻嗪酮药物分子的制备方法

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4632671B1 (es) * 1969-10-13 1971-09-23 Eisai Co Ltd
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
FI79651C (fi) 1982-10-08 1990-02-12 Glaxo Group Ltd Doseringsanordning foer medicin.
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
US4811731A (en) 1985-07-30 1989-03-14 Glaxo Group Limited Devices for administering medicaments to patients
JPH0733379B2 (ja) * 1986-06-27 1995-04-12 エーザイ株式会社 光学活性α−トコフエロ−ルの製造方法
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
SK280967B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Inhalačný prístroj
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
GB9700226D0 (en) 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
FR2798656B1 (fr) 1999-09-17 2004-12-17 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent
AU2001241332A1 (en) 2000-07-21 2002-02-05 Michail Michailovich Budjonnuj Plate for a stand-up meal
AU2001289749B9 (en) 2000-07-26 2004-08-19 Smithkline Beecham P.L.C. Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
FR2816618B1 (fr) 2000-11-15 2002-12-27 Aventis Pharma Sa Derives heterocyclylalcoyl piperidine, leur preparation et les compositions qui les contiennent
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
WO2002050036A1 (en) 2000-12-21 2002-06-27 Ciba Speciality Chemicals Holding Inc. Crystalline forms of cerivastatin sodium
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0118238D0 (en) 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
AU2003239302A1 (en) 2002-01-29 2003-09-02 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
JP4445753B2 (ja) 2002-01-29 2010-04-07 グラクソ グループ リミテッド アミノピペリジン誘導体
US20060014786A1 (en) * 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
TW200409637A (en) * 2002-06-26 2004-06-16 Glaxo Group Ltd Compounds
AR040335A1 (es) 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de ciclohexano o ciclohexeno, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento y compuestos intermediarios de utilidad para preparar dicho compuesto
CN100427487C (zh) 2002-06-27 2008-10-22 弗·哈夫曼·拉罗切有限公司 嘌呤衍生物的合成
GB0217294D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicaments
FR2844270B1 (fr) 2002-09-11 2006-05-19 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur procede et intermediaires de preparation et les compositions qui les contiennent
FR2844268B1 (fr) 2002-09-11 2004-10-22 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leurs procedes et intermediaires de preparation et les compositions qui les contiennent
ATE463494T1 (de) 2002-10-10 2010-04-15 Morphochem Ag Komb Chemie Neue verbindungen mit antibakterieller aktivität
ATE461928T1 (de) 2002-11-05 2010-04-15 Glaxosmithkline Llc Antibakterielle wirkstoffe
WO2004041210A2 (en) 2002-11-05 2004-05-21 Smithkline Beecham Corporation Antibacterial agents
AR042486A1 (es) 2002-12-18 2005-06-22 Glaxo Group Ltd Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion .
TW200507841A (en) * 2003-03-27 2005-03-01 Glaxo Group Ltd Antibacterial agents
FR2852954B1 (fr) 2003-03-28 2006-07-14 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
DE10316081A1 (de) 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
FR2858619B1 (fr) 2003-08-08 2006-12-22 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
MXPA06006738A (es) 2003-12-19 2006-08-31 Univ North Carolina Metodos para fabricar micro- y nano-estructuras aisladas utilizando litografia suave o de impresion.
US9214590B2 (en) 2003-12-19 2015-12-15 The University Of North Carolina At Chapel Hill High fidelity nano-structures and arrays for photovoltaics and methods of making the same
US8158728B2 (en) 2004-02-13 2012-04-17 The University Of North Carolina At Chapel Hill Methods and materials for fabricating microfluidic devices
FR2867472B1 (fr) 2004-03-12 2008-07-18 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
JP2008502689A (ja) 2004-06-15 2008-01-31 グラクソ　グループ　リミテッド 抗菌剤
FR2872164B1 (fr) 2004-06-29 2006-11-17 Aventis Pharma Sa Derives de quinoleines-4-substituees, leur procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
EP1773831A1 (en) 2004-07-08 2007-04-18 Glaxo Group Limited Antibacterial agents
US20080194547A1 (en) * 2004-07-09 2008-08-14 Glaxo Group Limited Antibacterial Agents
US7648984B2 (en) 2004-07-13 2010-01-19 Glaxo Group Limited Antibacterial agents
WO2006012396A1 (en) 2004-07-22 2006-02-02 Glaxo Group Limited Antibacterial agents
ATE484509T1 (de) 2004-08-02 2010-10-15 Glaxo Group Ltd Antibakterielle mittel
US20070161627A1 (en) 2004-08-09 2007-07-12 Miller William H Antibacterial agents
DE102004041163A1 (de) 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
WO2006032466A2 (en) 2004-09-24 2006-03-30 Actelion Pharmaceuticals Ltd New bicyclic antibiotics
CN101039935B (zh) 2004-10-05 2011-04-20 埃科特莱茵药品有限公司 哌啶抗生素
JP5314244B2 (ja) 2004-10-27 2013-10-16 富山化学工業株式会社 新規な含窒素複素環化合物およびその塩
EP1846417A4 (en) 2005-01-25 2009-12-23 Glaxo Group Ltd ANTIBACTERIAL ACTIVE SUBSTANCES
RU2007147413A (ru) 2005-05-24 2009-06-27 Астразенека Аб (Se) Аминопиперидинхинолины и их азаизостерические аналоги с антибактериальной активностью
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
WO2006137485A1 (ja) 2005-06-24 2006-12-28 Toyama Chemical Co., Ltd. 新規な含窒素複素環化合物およびその塩
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
WO2007081876A2 (en) 2006-01-04 2007-07-19 Liquidia Technologies, Inc. Nanostructured surfaces for biomedical/biomaterial applications and processes thereof
CA2635205C (en) * 2006-02-15 2014-06-10 Actelion Pharmaceuticals Ltd Ethanol or 1,2-ethanediol cyclohexyl antibiotic derivatives
KR101409261B1 (ko) 2006-05-26 2014-06-18 다이쇼 세이야꾸 가부시끼가이샤 신규의 복소환 화합물 또는 그 염 및 그 중간체
EP1992628A1 (en) 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
US8465775B2 (en) 2006-07-27 2013-06-18 The University Of North Carolina At Chapel Hill Nanoparticle fabrication methods, systems, and materials for fabricating artificial red blood cells
US8128393B2 (en) 2006-12-04 2012-03-06 Liquidia Technologies, Inc. Methods and materials for fabricating laminate nanomolds and nanoparticles therefrom
CL2007003693A1 (es) * 2006-12-22 2008-06-27 Actelion Pharmaceuticals Ltd Compuestos derivados de pirido [3,2-b] [1,4] tiazina; composicion farmaceutica que contiene dichos compuestos; y su uso en el tratamiento de infecciones bacterianas.
GB0707704D0 (en) * 2007-04-20 2007-05-30 Glaxo Group Ltd Compounds
WO2009024342A2 (en) * 2007-08-23 2009-02-26 Syngenta Participations Ag Novel microbiocides
EP2207670B1 (en) 2007-10-12 2019-05-22 Liquidia Technologies, Inc. Method for producing particles and patterned films
JP5620636B2 (ja) 2007-11-26 2014-11-05 富山化学工業株式会社 新規な複素環化合物またはその塩を含有する抗菌剤
DK2344495T3 (en) * 2008-10-07 2015-02-02 Actelion Pharmaceuticals Ltd TRICYCLIC OXAZOLIDINON ANTIBIOTIC COMPOUNDS
WO2010045987A1 (en) * 2008-10-23 2010-04-29 Glaxo Group Limited Substituted (aza) -1-methyl-1h-quin0lin-2-0nes as antibacterials
TW201022279A (en) * 2008-11-14 2010-06-16 Astrazeneca Ab Chemical compounds
WO2010065748A2 (en) 2008-12-05 2010-06-10 Liquidia Technologies, Inc. Method for producing patterned materials
MX2011005905A (es) * 2008-12-12 2011-06-20 Actelion Pharmaceuticals Ltd Derivados de 5-amino-2-(1-hidroxi-etil)-tetrahidropirano.
JP5656996B2 (ja) 2009-07-13 2015-01-21 ザ ユニバーシティ オブ ノース キャロライナ アット チャペル ヒル 工学的に作製されたエアロゾル粒子、およびそれに関連した方法
TW201209056A (en) * 2010-05-25 2012-03-01 Taisho Pharmaceutical Co Ltd Novel heterocyclic compound or salt thereof
CA2840060A1 (en) * 2011-06-27 2013-01-03 Kyorin Pharmaceutical Co., Ltd. Bridged bicyclic compounds for the treatment of bacterial infections
EP2785721A1 (en) * 2011-11-30 2014-10-08 Actelion Pharmaceuticals Ltd. 3,7-disubstituted octahydro-2h-pyrido[4,3-e][1,3]oxazin-2-one antibiotics
AU2014255326B2 (en) 2013-04-16 2018-09-13 Idorsia Pharmaceuticals Ltd Antibacterial biaromatic derivatives
TW201722965A (zh) * 2015-08-16 2017-07-01 葛蘭素史密斯克藍智慧財產發展有限公司 用於抗菌應用之化合物

Also Published As

Publication number Publication date
US20190270755A1 (en) 2019-09-05
WO2017029602A2 (en) 2017-02-23
AU2016307969C1 (en) 2019-09-05
MX2018002033A (es) 2018-06-15
PE20181143A1 (es) 2018-07-17
MA42621A (fr) 2018-06-20
JP2018523675A (ja) 2018-08-23
KR20180038046A (ko) 2018-04-13
AU2016307969B2 (en) 2019-02-14
UY36851A (es) 2017-03-31
PH12018500358A1 (en) 2018-09-03
DOP2018000049A (es) 2018-03-30
US20190031680A1 (en) 2019-01-31
AU2019200226B2 (en) 2020-01-23
TW201722965A (zh) 2017-07-01
EA201890412A1 (ru) 2018-08-31
AU2016307969A1 (en) 2018-03-08
CA2995715A1 (en) 2017-02-23
EP3334739A2 (en) 2018-06-20
HK1248680A1 (zh) 2018-10-19
EA033314B1 (ru) 2019-09-30
CN108137616B (zh) 2020-06-26
CO2018002204A2 (es) 2018-06-20
US10683307B2 (en) 2020-06-16
US10364254B2 (en) 2019-07-30
ZA201800722B (en) 2019-07-31
CN108137616A (zh) 2018-06-08
IL257265B (en) 2020-07-30
JP6757402B2 (ja) 2020-09-16
WO2017029602A3 (en) 2017-04-13
CL2018000403A1 (es) 2018-07-06
AU2019200226A1 (en) 2019-01-31
IL257265A (en) 2018-03-29

Similar Documents

Publication Publication Date Title
GT201600183A (es) Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas
CR20170237A (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
CL2015001667A1 (es) Derivados de manosa para tratar infecciones bacterianas.
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
GT201700058A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
AR103680A1 (es) Inhibidores selectivos de bace1
DOP2019000193A (es) Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende
ECSP16074478A (es) Compuestos novedosos
CO2018002204A2 (es) Agentes antibacteriales que comprenden un pirazino [2,3-b]- [1,4] oxazin-3-ona o un sistema de anillo relacionado
EA201692032A1 (ru) Антибактериальные соединения
CL2015000608A1 (es) Formulaciones de daptomicina y usos de la misma
UY36124A (es) Derivados de carboxamida
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
UY35359A (es) 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS SUSTITUIDAS Y MÉTODOS DE USO
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
UY36123A (es) Derivados de carboxamida
GT201700016A (es) [1,2,4] triazolo [4,3 -b] piridazinas para su uso en el tratamiento de enfermedades proliferativas
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
UY36228A (es) Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen
PE20170430A1 (es) Arilhidrazidas que contienen una fraccion de 2-piridona como agentes antibacterianos selectivos
CL2016001024A1 (es) Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades.
BR112017004595A2 (pt) composição farmacêutica contendo inibidor de transportador de fosfato dependente de sódio
AR109209A1 (es) Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas